Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2020 American Academy of Ophthalmology November 15, 2020
Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical Trials November 13, 2020
Beam Therapeutics Presents First Data Highlighting Base Editing Program for Glycogen Storage Disease Type Ia at AASLD November 13, 2020
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC November 12, 2020
PatientPing Partners with MedAllies to Ensure Hospital Partners’ Compliance with CMS E-Notifications Condition of Participation November 10, 2020
Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II) November 10, 2020
Innovent Releases Phase 1a Results of CD47 Monoclonal Antibody (Letaplimab) in Monotherapy for Advanced Malignancies at SITC 2020 November 10, 2020
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC November 9, 2020
Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen November 9, 2020